Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30764
Abstract: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13‐valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding… read more here.
Keywords: conjugate vaccine; valent pneumococcal; oncology; pneumococcal conjugate ... See more keywords
Impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on acute mastoiditis in children in southern Israel: A 12-year retrospective comparative study (2005-2016).
Sign Up to like & getrecommendations! Published in 2020 at "International journal of pediatric otorhinolaryngology"
DOI: 10.1016/j.ijporl.2020.110485
Abstract: OBJECTIVES To define the trends in acute mastoiditis (AM) incidence, microbiology, complications and management in children, before and after the 13-valent pneumococcal conjugate vaccine (PVC13) introduction. METHODS Medical records of all AM patients read more here.
Keywords: acute mastoiditis; study; conjugate vaccine; valent pneumococcal ... See more keywords
Methods for estimating the direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years in Matiari, Pakistan
Sign Up to like & getrecommendations! Published in 2021 at "MethodsX"
DOI: 10.1016/j.mex.2021.101357
Abstract: Pneumonia is the leading cause of morbidity and mortality in children worldwide. The ten valent pneumococcal vaccine (PCV10) was introduced in Pakistan's Expanded Program on Immunization (EPI) in 2012 as a 3 + 0 schedule… read more here.
Keywords: direct indirect; pneumococcal vaccine; nasopharyngeal carriage; valent pneumococcal ... See more keywords
Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2016.12.070
Abstract: Objective The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness… read more here.
Keywords: vaccination mongolia; cost effectiveness; valent pneumococcal; vaccination ... See more keywords
Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: The emergence of multidrug resistant serotype 6C.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.04.019
Abstract: BACKGROUND In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced free of charge in Brazil as part of the public immunization program. Here we investigated the carriage prevalence, colonization risk factors, capsular types, and… read more here.
Keywords: use; conjugate vaccine; valent pneumococcal; carriage ... See more keywords
Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.07.043
Abstract: Brazil introduced the 10-valent pneumococcal vaccine (PCV10) to the routine national immunization program (NIP) in March 2010. In 2017, we investigated the effects of PCV10 on nasopharyngeal carriage of vaccine-types (VT) and non-vaccine-types (NVT) of… read more here.
Keywords: nasopharyngeal carriage; valent pneumococcal; streptococcus pneumoniae; vaccine ... See more keywords
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.08.048
Abstract: INTRODUCTION Streptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial morbidity and mortality, particularly in those under 2 years of age and those over 65 years of age. While… read more here.
Keywords: healthy adults; conjugate vaccine; valent pneumococcal; vaccine ... See more keywords
Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine.
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.04.063
Abstract: Different schedules for pediatric use of the 13-valent pneumococcal conjugate vaccine (PCV-13) are recommended in different countries and the U.S. Advisory Committee on Immunization Practices (ACIP) has considered potential of changing from 3 primary doses… read more here.
Keywords: booster; antibody; conjugate vaccine; valent pneumococcal ... See more keywords
Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.08.068
Abstract: Pneumococcal disease is a substantial contributor to illness and death in young children globally. The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 had a significant impact in preventing pneumococcal disease in both vaccinated… read more here.
Keywords: health impact; impact; valent pneumococcal; public health ... See more keywords
Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
Sign Up to like & getrecommendations! Published in 2021 at "Vaccine"
DOI: 10.1016/j.vaccine.2021.06.075
Abstract: BACKGROUND In China, 13-valent pneumococcal conjugate vaccine (PCV13) has been available since 2017, but only via the private market with low uptake rate. We assessed the direct effectiveness of PCV13 against community acquired pneumonia (CAP)… read more here.
Keywords: among children; cohort; valent pneumococcal; vaccine ... See more keywords
Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
Sign Up to like & getrecommendations! Published in 2022 at "Vaccine"
DOI: 10.1016/j.vaccine.2022.03.048
Abstract: We used an indirect cohort analysis in children under 5 years-old from 2002 to 2018 to examine vaccine effectiveness (VE) of the 7-valent pneumococcal conjugate vaccine (PCV) (3 + 1 doses in most regions) and the 13-valent PCV… read more here.
Keywords: valent pneumococcal; vaccine effectiveness; effectiveness; effectiveness valent ... See more keywords